Literature DB >> 7964671

Five-factor model of schizophrenia. Initial validation.

J P Lindenmayer1, R Bernstein-Hyman, S Grochowski.   

Abstract

Schizophrenic psychopathology is heterogeneous and multidimensional. Various strategies have been developed over the past several years to assess and measure more accurately discrete domains of psychopathology. One of the more fruitful strategies to investigate more homogenous domains of psychopathology has been the positive-negative syndrome approach. However, this approach is unable to address a number of important issues. Most schizophrenics present a mixed syndrome; the criteria for what constitutes a positive and negative syndrome are variable; distinguishing primary from secondary negative symptoms can be difficult. In order to address some of these problems, we propose the introduction of a five-syndrome model based on a reanalysis of factor analytic procedures used on 240 schizophrenics assessed with the Positive and Negative Syndrome Scale. We present data on a five-factor solution that appears to best fit the psychopathological data and that is supported by three independent and comparable factor analyses; negative, positive, excitement, cognitive, and depression/anxiety domains of psychopathology give patients their individual mark. Data on internal consistency of the five factors and on initial validation using demographic and clinical variables are presented.

Entities:  

Mesh:

Year:  1994        PMID: 7964671     DOI: 10.1097/00005053-199411000-00006

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  44 in total

Review 1.  Symptom dimensions in the course of childhood-onset schizophrenia.

Authors:  D Bunk; C Eggers; M Klapal
Journal:  Eur Child Adolesc Psychiatry       Date:  1999       Impact factor: 4.785

2.  Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia.

Authors:  Martin P Cruz
Journal:  P T       Date:  2011-08

3.  Symptom dimensions and outcome in schizophrenia.

Authors:  Raimo K R Salokangas
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

4.  Immersion in altered experience: An investigation of the relationship between absorption and psychopathology.

Authors:  Cherise Rosen; Nev Jones; Kayla A Chase; Jennifer K Melbourne; Linda S Grossman; Rajiv P Sharma
Journal:  Conscious Cogn       Date:  2017-02-20

5.  Comparison of visual perceptual organization in schizophrenia and body dysmorphic disorder.

Authors:  Steven M Silverstein; Corinna M Elliott; Jamie D Feusner; Brian P Keane; Deepthi Mikkilineni; Natasha Hansen; Andrea Hartmann; Sabine Wilhelm
Journal:  Psychiatry Res       Date:  2015-06-27       Impact factor: 3.222

6.  Reading impairment and visual processing deficits in schizophrenia.

Authors:  Nadine Revheim; Pamela D Butler; Isaac Schechter; Maria Jalbrzikowski; Gail Silipo; Daniel C Javitt
Journal:  Schizophr Res       Date:  2006-08-04       Impact factor: 4.939

7.  Amusia and protolanguage impairments in schizophrenia.

Authors:  J T Kantrowitz; N Scaramello; A Jakubovitz; J M Lehrfeld; P Laukka; H A Elfenbein; G Silipo; D C Javitt
Journal:  Psychol Med       Date:  2014-03-31       Impact factor: 7.723

8.  Auditory processing in schizophrenia during the middle latency period (10-50 ms): high-density electrical mapping and source analysis reveal subcortical antecedents to early cortical deficits.

Authors:  Victoria M Leavitt; Sophie Molholm; Walter Ritter; Marina Shpaner; John J Foxe
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

9.  Determinants of objective and subjective quality of life in first-time-admission schizophrenic patients in Poland: a longitudinal study.

Authors:  Krystyna Górna; Krystyna Jaracz; Filip Rybakowski; Janusz Rybakowski
Journal:  Qual Life Res       Date:  2007-12-28       Impact factor: 4.147

10.  The self-assessment scale of cognitive complaints in schizophrenia: a validation study in Tunisian population.

Authors:  Ines Johnson; Oussama Kebir; Olfa Ben Azouz; Lamia Dellagi; Yasmine Rabah; Karim Tabbane
Journal:  BMC Psychiatry       Date:  2009-10-08       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.